FrancophonIA/ELRC3.0 huggingface dataset:
English: Suppressing the immune system with corticosteroid medicines can bring the disease under control, but these medicines can have marked side effects and affect growth in young patients.
Estonian: Haigust on võimalik reguleerida immuunsüsteemi supresseerimisega kortikosteroididega, kuid nendel ravimitel võivad olla märkimisväärsed kõrvalnähud ning need võivad pidurdada pediaatriliste patsientide kasvu.
English: Based on the review of the data, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Elmisol could not have been approved for the treatment of nephrotic syndrome.
Estonian: Tuginedes esitatud andmete analüüsile, nägi komitee taotluse tagasivõtmise ajal põhjust ettevaatlikkuseks ja oli esialgsel seisukohal, et ravimi Elmisol kasutamist nefrootilise sündroomi raviks ei ole võimalik heaks kiita.
English: Elmisol was designated an ‘orphan medicine' (a medicine to be used in rare diseases) on 28 October 2005 for nephrotic syndrome.
Estonian: Elmisol nimetati 28. oktoobril 2005 nefrootilise sündroomi harvikravimiks (ravim, mida kasutatakse harvaesinevate haiguste korral).
English: What was Elmisol expected to be used for?
Estonian: Milleks kavatseti Elmisoli kasutada?
English: Elmisol was to be used in children from 2 years of age to treat nephrotic syndrome.
Estonian: Elmisoli kavatseti kasutada nefrootilise sündroomi raviks vähemalt 2-aastastel lastel.
English: Packaging Content Package size Withdrawal Period
Estonian: Sisaldus Pakendi suurus
English: 1 bottle
Estonian: 500 ml 1 pudel
English: Target species Route of administration
Estonian: Tugevus Ravimvorm Loomaliigid Manustamisviis Pakend
English: 10 bottles
Estonian: 500 ml 10 pudelit 0 päeva
English: --1 1 dose (0.5 ml) contains approximately:
Estonian: --1 1 annus (0,5 ml) sisaldab ligikaudu:
English: ² L1 protein in the form of virus-like particles produced in yeast cells (Saccharomyces cerevisiae CANADE 3C-5 (Strain 1895)) by recombinant DNA technology
Estonian: ² L1-valk viiruste moodi osakestena, mis on toodetud pärmirakkudes (Saccharomyces cerevisiae CANADE 3C-5 (tüvi 1895)) kasutades rekombinantset DNA tehnoloogiat.
English: 10 syringes
Estonian: 10 süstlit
English: ¹ Human Papillomavirus = HPV
Estonian: ¹ Inimese papilloomiviirus, human papillomavirus, HPV
English: 10 syringes + 20 needles
Estonian: 10 süstlit + 20 nõela
English: ³ adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (0.5 milligrams Al)
Estonian: ³ Adsorbeerituna vaktsiinide abiainele amorfsele alumiiniumhüdroksüfosfaatsulfaadile (0,5 milligrammi alumiiniumi)
English: 1 syringe + 2 needles
Estonian: 1 süstel + 2 nõela
English: Pack size vial (glass)
Estonian: Süstesuspensioon Intramuskulaarne viaal (klaas)
English: 18 December 2018
Estonian: 18. detsember 2018
English: What is Perlinring?
Estonian: Mis on Perlinring?
English: The Agency concluded that the benefits of Perlinring outweigh its risks, and the marketing authorisation can be granted in the United Kingdom and in the following Member States of the EU: Austria, Belgium, Croatia, Czech Republic, Denmark, Estonia, Spain, Finland, France, Germany, Hungary, Ireland, Italy, Lithuania, Latvia, the Netherlands, Poland, Portugal, Romania, Slovenia, Slovakia and Sweden, plus Iceland and Norway.
Estonian: EMA järeldas, et Perlinringi kasulikkus on suurem kui kaasnevad riskid ning seega saab anda müügiloa Ühendkuningriigis ja järgmistes Euroopa Liidu liikmesriikides: Austria, Belgia, Eesti, Hispaania, Horvaatia, Iirimaa, Itaalia, Leedu, Läti, Madalmaad, Poola, Portugal, Prantsusmaa, Rootsi, Rumeenia, Saksamaa, Slovakkia, Sloveenia, Soome, Taani, Tšehhi Vabariik ja Ungari, samuti Islandil ja Norras.
English: The European Commission issued an EU-wide legally binding decision on 18 December 2018.
Estonian: Euroopa Komisjon tegi kogu Euroopa Liidus õiguslikult siduva otsuse 18. detsembril 2018.
English: The review of Perlinring was initiated at the request of the United Kingdom, under Article 29 of Directive 2001/83/EC.
Estonian: Perlinringi ravimiteabe läbivaatamine algas Ühendkuningriigi taotlusel vastavalt direktiivi 2001/83/EÜ artiklile 29.
English: Each ring contains two hormones, etonogestrel and ethinylestradiol, which are slowly released into the blood circulation and prevent the release of eggs from the ovaries.
Estonian: Iga rõngas sisaldab kaht hormooni, etonogestreeli ja etinüülöstradiooli, mis aeglaselt vabanevad vereringesse ja takistavad munarakkude vabanemist munasarjadest.
English: Perlinring is used for 21 days (3 weeks) in a row, followed by a 7-day break, after which a new ring should be used.
Estonian: Perlinringi kasutatakse korraga 21 päeva (3 nädalat), millele järgneb 7-päevane vaheaeg, pärast mida tuleb kasutada uut rõngast.
English: Perlinring was developed as a generic medicine.
Estonian: Perlinring töötati välja geneerilise ravimina.
English: This is a procedure where one Member State (the ‘reference Member State', in this instance the United Kingdom) assesses a medicine with a view to granting a marketing authorisation that will be valid in this country as well as in other Member States (the ‘concerned' Member States, see list above) where the company has applied for a marketing authorisation.
Estonian: See on menetlus, milles üks liikmesriik (viiteliikmesriik, praegusel juhul Ühendkuningriik) hindab ravimit, et otsustada, kas anda ravimi müügiluba oma riigis ja muudes liikmesriikides, kus ettevõte on esitanud müügiloa taotluse (asjaomased liikmesriigid, vt loetelu ülal).
English: Why was Perlinring reviewed?
Estonian: Miks Perlinringi ravimiteave uuesti läbi vaadati?
English: Actavis Group PTC EHF submitted Perlinring to the UK medicines agency for a decentralised procedure.
Estonian: Actavis Group PTC EHF esitas Ühendkuningriigi ravimiametile Perlinringi detsentraliseeritud menetlusega heakskiitmise taotluse.
English: On 18 October 2018, the European Medicines Agency completed a review of Perlinring following a disagreement among EU Member States regarding its authorisation.
Estonian: 18. oktoobril 2018 lõpetas Euroopa Ravimiamet (EMA) Perlinringi ravimiteabe läbivaatamise, mille oli põhjustanud Euroopa Liidu liikmesriikide erimeelsus seoses müügiloa andmisega.
English: The Agency therefore concluded that the benefits of Perlinring outweigh its risks and recommended that the marketing authorisation be granted in all concerned Member States.
Estonian: EMA järeldas seega, et Nuvaringi kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda müügiloa kõigis asjaomastes liikmesriikides.
English: The grounds for the referral relate to concerns raised by Germany, France and the Netherlands, that the Nuvaring product information for doctors and patients states that the product continues to be effective if it is used for an additional 4th week.
Estonian: Esildise põhjused on seotud Madalmaade, Prantsusmaa ja Saksamaa tõstatatud probleemiga, et Nuvaringi ravimiteave arstidele ja patsientidele kinnitab, et toote efektiivsus jätkub kasutamisel täiendava 4. nädala jooksul.
English: Perlinring is a contraceptive vaginal ring used to prevent pregnancy.
Estonian: Perlinring on rasestumisvastane tuperõngas, mida kasutatakse raseduse ennetamiseks.
English: However, the Member States were not able to reach an agreement and the UK medicines regulatory agency referred the matter to EMA for arbitration on 7 August 2018.
Estonian: Liikmesriigid ei jõudnud üksmeelele ja Ühendkuningriigi ravimiamet tegi 7. augustil 2018 EMA-le vahekohtumenetluse alustamise esildise.
English: medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.
Estonian: Kaks ravimit on bioekvivalentsed, kui mõlemad tekitavad organismis sama toimeainesisalduse ja seetõttu on eeldatav toime ühesugune.
English: Although the bioequivalence data submitted were sufficient to show that Perlinring is bioequivalent to Nuvaring over a period of 3 weeks, they did not cover the additional 4th week during which the contraceptive ring may still be used, even though this use is not recommended.
Estonian: Kuigi esitatud bioekvivalentsusandmed olid piisavad tõendamaks, et Perlinring on 3 nädala jooksul Nuvaringiga bioekvivalentne, ei hõlmanud see täiendavat 4. nädalat, mille jooksul rasestumisvastast rõngast saab veel kasutada, kuigi sellist kasutamist ei soovitata.
English: Bioequivalence data for week 4 were considered necessary by Germany, France and the Netherlands as Perlinring is expected to be used in the same way as Nuvaring.
Estonian: Madalmaad, Prantsusmaa ja Saksamaa pidasid 4. nädala bioekvivalentsuse andmeid vajalikuks, sest Perlinringi kasutatakse eeldatavasti samamoodi kui Nuvaringi.
English: This means that Perlinring was developed to contain the same active substance and work in the same way as a ‘reference medicine' already authorised in the EU called Nuvaring.
Estonian: See tähendab, et Perlinring sisaldab sama toimeainet ja toimib samamoodi nagu võrdlusravim Nuvaring, millel juba on ELis müügiluba.
English: Based on evaluation of the currently available data, the Agency considered that bioequivalence to the reference medicinal product has been shown for the authorised duration of treatment (3 weeks).
Estonian: Tuginedes praegu kättesaadavate andmete hindamisele, leidis EMA, et ravimi bioekvivalentsus võrdlusravimiga heakskiidetud ravikestuse ajal (3 nädalat) on tõendatud.
English: In addition, there is enough evidence to expect that Perlinring continues to be effective for an additional 4th week, as is the case for Nuvaring.
Estonian: Lisaks on piisavalt andmeid, et Perlinring on täiendava 4. nädala jooksul jätkuvalt efektiivne nagu Nuvaring.
English: In its application, the company for Perlinring provided data demonstrating that Perlinring is ‘bioequivalent' to Nuvaring over a period of 3 weeks, which is the authorised length of treatment.
Estonian: Perlinringi ettevõte esitas oma taotluses andmed, mis tõendavad Perlinringi bioekvivalentsust Nuvaringiga 3 nädala jooksul, mis on heakskiidetud ravikestus.
English: EMEA/458933/2008-EN
Estonian: EMEA/458933/2008-ET
English: The Marketing Authorisation Holder was requested: 1.
Estonian: Müügiloa hoidjal paluti teha järgmist: 1.
English: The CVMP Opinion was adopted on 11 October 2007 and the subsequent Commission Decision on 11 January 2008.
Estonian: Veterinaarkomitee arvamus võeti vastu 11. oktoobril 2007 ja selle põhjal komisjoni otsus 11. jaanuaril
English: To justify compliance of the dossier with respect to the requirements for obtaining a marketing authorisation (Annex I of Directive 2001/82/EC, as amended).
Estonian: Põhjendada toimiku vastavust müügiloa saamise nõuetele (muudetud direktiivi 2001/82/EÜ I lisa).
English: The CVMP started the referral procedure during its meeting of 12-14 September 2006.
Estonian: Veterinaarravimite komitee alustas esildismenetlust 12.-14. septembri 2006 koosolekul.
English: To provide the relevant parts of the dossier of each Member State where an application has been submitted and to detail the differences between the dossiers.
Estonian: Esitada toimiku asjakohased osad iga liikmesriigi kohta, kus taotlus on esitatud, ja tuua välja erinevused toimikute vahel.
English: OPINION FOLLOWING AN ARTICLE 34 REFERRAL FOR METHOXASOL-T
Estonian: ARVAMUS PÄRAST ARTIKLI 34 KOHAST ESILDIST METHOXASOL-T
English: Methoxasol-T was authorised through a national procedure in The Netherlands in 1999, but a marketing authorisation was refused in Germany in 2001.
Estonian: Ravimile Methoxasol-T anti müügiluba Madalmaades riikliku menetluse käigus 1999. aastal, kuid Saksamaal keelduti 2001. aastal müügiluba andmast.
English: Germany considered that the efficacy of Methoxasol-T as proposed by the applicant was not adequately justified, therefore resulting in a potential serious risk to the target animals.
Estonian: Saksamaa leidis, et ravimi Methoxasol-T efektiivsuse andmed, mille esitas taotleja, ei olnud piisavalt põhjendatud ja ravim võib põhjustada seega sihtloomadele võimalikku suurt riski.
English: On 8 September 2006, Germany presented to the EMEA a referral under Article 34 of Directive 2001/82/EC, as amended, concerning Methoxasol-T (including associated names), containing trimethoprim and sulfamethoxazole as active ingredient.
Estonian: 8. septembril 2006 esitas Saksamaa Euroopa Ravimiametile muudetud direktiivi 2001/82/EÜ artikli 34 kohase esildise toimeainena trimetopriimi ja sulfametoksasooli sisaldava ravimi Methoxasol-T (ja seotud nimetuste) kohta.
English: On the basis of the data provided, the CVMP agreed on the following harmonised indications for use:
Estonian: Esitatud andmete alusel nõustus veterinaarravimite komitee järgmiste ühtlustatud näidustustega:
English: An intended application for a marketing authorisation of a generic triggered Germany to submit the referral regarding the divergent decisions taken on Methoxasol-T.
Estonian: Geneerilisele ravimile esitatud müügiloa taotlus oli ajend, mille tõttu Saksamaa tegi esildise seoses Methoxasol-T kohta tehtud lahknevate otsustega.
English: To consider in particular the issues mentioned in the referral notification as the grounds for refusing an authorisation in Germany.
Estonian: Kaaluda eelkõige konkreetseid küsimusi, mida mainitakse esildisteatises müügiloa andmisest keeldumise alustena Saksamaal.
English: Having considered the grounds for referral and the responses provided by the Marketing Authorisation Holder, CVMP concluded that the benefit/risk balance of the product is positive for use in both pigs and broilers subject to recommended changes to the Summary of Product Characteristics and product information, and that the concerns raised by Germany should not prevent the granting of a marketing authorisation.
Estonian: Olles kaalunud esildise aluseid ja müügiloa hoidja esitatud vastuseid, leidis veterinaarravimite komitee, et toote kasulikkuse ja riski suhe ravimi omaduste kokkuvõtte ja ravimiteabe soovitatavate muudatuste korral on nii sigade kui ka broilerite jaoks positiivne ning et Saksamaa tõstatatud küsimused ei takista müügiloa andmist.
English: To propose and justify with data a suitable shelf life for the product, including an in-use shelf life where relevant.
Estonian: Pakkuda välja ja põhjendada andmetega toote sobivat säilitusaega, sealhulgas säilitusaega kasutamise ajal, kus see on asjakohane.
English: For poultry comment was required on the current use of the product, in particular on the dose used or prescribed under field conditions.
Estonian: Kodulindude osas nõuti selgitust toote praeguse kasutamise kohta, eriti annuse kohta, mida kasutatakse või määratakse välitingimustes.
English: The CVMP recommended in relation to the pharmacokinetic properties described that the inclusion of environmental effects should be deleted.
Estonian: Veterinaarravimite komitee soovitas seoses kirjeldatud farmakokineetiliste omadustega kustutada keskkonnamõjude osa.
English: The Marketing Authorisation Holder submitted written responses, defending the indications, recommended dose and shelf life, and proposing a harmonised SPC text.
Estonian: Müügiloa hoidja esitas kaks kirjalikku vastust, mis kaitsesid näidustusi, soovitatavat annust ja säilitusaega, ning pakkus välja ravimi omaduste kokkuvõtte ühtlustatud teksti.
English: • Broilers: treatment and prevention of respiratory infections caused by Escherichia coli susceptible to trimethoprim and sulfamethoxazole where the disease has been diagnosed in the flock.
Estonian: • Broilerid: trimetopriimile ja sulfametoksasoolile tundliku bakteri Escherichia coli põhjustatud respiratoorsete infektsioonide ravi ja ennetamine, kui haigus on karjas diagnoositud.
English: The CVMP also recommended that the use of the product should be based on culture and sensitivity testing of micro-organisms from diseased cases on farm or from recent previous experience on the farm, as resistance against potentiated sulphonamides may vary.
Estonian: loomadelt pärit mikroorganismide kultuuril ja tundlikkuse katsetel või hiljutisel varasemal kogemusel, sest resistentsus tugevdatud sulfoonamiidide suhtes võib olla erinev.
English: • Pigs: treatment and prevention of respiratory infections caused by Actinobacillus pleuropneumoniae susceptible to trimethoprim and sulfamethoxazole where the disease has been diagnosed in the herd.
Estonian: • Sead: trimetopriimile ja sulfametoksasoolile tundliku bakteri Actinobacillus pleuropneumoniae põhjustatud respiratoorsete infektsioonide ravi ja ennetamine, kui haigus on karjas diagnoositud.
English: To propose and justify a harmonised text of the Summary of Product Characteristics (SPC), including posology and method of administration as well as withdrawal periods for pigs and poultry.
Estonian: Pakkuda välja ravimi omaduste kokkuvõtte ühtlustatud tekst koos põhjendustega, sealhulgas annustamise ja manustamisviisi ning sigade ja kodulindude keeluaegade kohta.
English: To justify with field data, the use of the product and the adequacy of the recommended dose for each of the claimed indications in pigs and poultry.
Estonian: Põhjendada väliandmetega toote kasutamise ja soovitatava annuse adekvaatsust iga taotletud näidustuse jaoks sigadel ja kodulindudel.
English: The European Commission granted a marketing authorisation valid throughout the EU for Simparica on 6 November 2015.
Estonian: Euroopa Komisjon andis Simparica müügiloa, mis kehtib kogu Euroopa Liidus, 6. novembril 2015.
English: What is Simparica and what is it used for?
Estonian: Mis on Simparica ja milleks seda kasutatakse?
English: Sarolaner
Estonian: Simparica sarolaneer
English: The full EPAR for Simparica can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Simparica kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: The tablets should be kept in the original package until use in order to prevent children directly accessing the medicine.
Estonian: Tablette tuleb hoida originaalpakendis kuni kasutamiseni, et takistada ravimi sattumist laste kätte.
English: Other information about Simparica
Estonian: Muu teave Simparica kohta
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Simparica's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Veterinaarravimite komitee järeldas, et Simparica kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: It is not intended to provide practical advice on how to use Simparica.
Estonian: Hindamisaruandes ei anta Simparica kasutamise praktilisi nõuandeid.
English: Why is Simparica approved?
Estonian: Miks Simparica heaks kiideti?
English: For treatment of ear mite infestations a single dose should be given.
Estonian: Kõrvasügelislestanakkuste raviks tuleb anda üks annus.
English: What are the risks associated with Simparica?
Estonian: Mis riskid Simparicaga kaasnevad?
English: Simparica was as effective as moxidectin/imidacloprid and the percentage of Simparica-treated dogs with no live mites was 15%, 69%, 93%, 94%, 100% and 100% on days 30, 60, 90, 120, 150 and 180, respectively.
Estonian: Simparica oli sama efektiivne kui moksidektiin/imidaklopriid: eluslestadeta koeri oli Simparica ravirühmas 30., 60., 90., 120., 150. ja 180. päeval vastavalt 15%, 69%, 93%, 94%, 100% ja 100%.
English: Treatment should be continued until skin scrapings are negative on at least two consecutive occasions one month apart.
Estonian: Ravi tuleb jätkata, kuni nahakaape tulemused on negatiivsed vähemalt kahel järjestikusel juhul kuuajase vahega.
English: How does Simparica work?
Estonian: Kuidas Simparica toimib?
English: These signs usually resolve without treatment.
Estonian: Need nähud kaovad tavaliselt ravita.
English: Simparica is available as chewable tablets (5, 10, 20, 40, 80 and 120 mg) and can only be obtained with a prescription.
Estonian: Simparicat turustatakse närimistablettidena (5, 10, 20, 40, 80 ja 120 mg).
English: It contains the active substance sarolaner.
Estonian: Ravim sisaldab toimeainena sarolaneeri.
English: Dogs with live mites on day 30 after initial treatment received a second treatment.
Estonian: Kui koeral oli 30. päeval pärast ravi algust eluslestad, tehti teine ravikuur.
English: In order to be exposed to the active substance, fleas and ticks must attach to the skin and commence feeding on the dog's blood.
Estonian: Toimeainega kokkupuutumiseks peavad kirbud ja puugid kinnituma nahale ning imema koera verd.
English: However, the following side effects are seen in less than 1 dog in 10,000: mild and short-lived vomiting and diarrhoea as well as tremor (shaking), ataxia (inability to coordinate body movements) or convulsions.
Estonian: Vähem kui 1 koeral 10 000st on siiski esinenud järgmised kõrvalnähud: kerge lühiajaline oksendamine ja kõhulahtisus, samuti treemor (värin), ataksia (liigutuste koordinatsioonihäired) või konvulsioonid.
English: Simparica is a veterinary medicine used to treat infestations with ticks and fleas, demodectic and sarcoptic mange (skin infestations caused by two different types of mites) and ear mite infestations in dogs.
Estonian: Simparica on veterinaarravim, mida kasutatakse puugi- ja kirbunakkuste, demodektoosi ja sarkoptoosi (kahe eri lesta põhjustatud nahanakkused) ja kõrvasügelislestanakkuste raviks koertel.
English: Because fleas and ticks must start feeding on the dog in order to be killed by the medicine, the risk of transmission of diseases with which they may be infected cannot be excluded.
Estonian: Kuivõrd ravimi toime avaldumiseks peavad kirbud ja puugid imema koera verd, ei saa välistada haiguste levimise riski nakatunud parasiitide kaudu.
English: As other conditions contribute to demodectic mange, any underlying diseases should also be treated.
Estonian: Et demodektoosi võivad soodustada ka muud haigused, tuleb ravida kõiki demodektoosiga seotud haigusi.
English: Simparica was as effective as moxidectin/imidacloprid.
Estonian: Simparica oli sama efektiivne kui moksidektiin/imidaklopriid.
English: This results in uncontrolled activity of the nervous system and the paralysis and death of the parasites.
Estonian: See häirib parasiitide närvisüsteemi talitlust, põhjustades nende paralüüsi ja surma.
English: Simparica can be used as part of the management of flea allergy dermatitis (an allergic reaction to flea bites).
Estonian: Ravimit tohib kasutada kirbuallergiast põhjustatud dermatiidi (allergiline reaktsioon kirbuhammustustele) ravi osana.
English: Sarolaner kills fleas before they can lay eggs and so helps to reduce contamination of the dog's environment.
Estonian: Sarolaneer hävitab kirbud, enne kui nad jõuavad muneda, mis aitab vähendada parasiitide levikut koera ümbruskonnas.
English: It blocks the normal movement of charged chloride particles (ions) in and out of nerve cells, especially those associated with gamma-aminobutyric acid (GABA) and glutamate, two substances that convey messages between nerves (neurotransmitters).
Estonian: Toimeaine takistab eelkõige neurotransmitterite (vahendavad närvirakkudevahelisi signaale) gammaaminovõihappe (GABA) ja glutamaadiga seotud kloriidiioonide normaalset liikumist närvirakkudesse ja neist välja.
English: For treatment of demodectic mange Simparica should be given once a month for at least three months.
Estonian: Demodektoosi raviks tuleb Simparicat manustada kord kuus vähemalt kolm kuud.
English: Safety information has been included in the summary of product characteristics and the package leaflet for Simparica, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
Estonian: Ravimi omaduste kokkuvõttesse ja pakendi infolehele lisati Simparica ohutusteave, kus on ka tervishoiuspetsialistide ja loomaomanike või -pidajate võetavad meetmed.
English: A field study was conducted in dogs infested with at least three live attached ticks.
Estonian: Ühes väliuuringus uuriti koeri, kellel leiti vähemalt kolm elusat nahale kinnitunud puuki.